Department of Pathology, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE.
Department of Pathology, Shaikh Zayed Medical Complex, Lahore, Pakistan.
Asian Pac J Cancer Prev. 2022 Mar 1;23(3):971-975. doi: 10.31557/APJCP.2022.23.3.971.
Background: Personalized medicine has played very important role in management of breast cancer. Proliferative index is one among the prognostic and predictive factor but unfortunately due to varied reports , no definite consensus and routine medical practice has been approved for it. The objective of the study is to observe the association of Ki-67 index using St. Gallen Conference criteria in invasive ductal carcinoma breast in Pakistani Population. Methods: Eighty-three patients with confirmed light microscopic diagnosis of primary invasive ductal carcinoma were recruited in this prospective study . Expression of Ki67 was determined by classifying as low (<15%) and high (>15%) Ki67 in tumour. Statistical analysis was performed to observe the association of Ki-67 with clinicopathological parameters and molecular group (i.e., Luminal A, Luminal B, Her2 enriched and triple negative). Results: Out of 83 patients, 73.5% of patients showed >15% Ki67 (p value <0.001). High expression of Ki 67 (>15%) was observed in 3.6%, 21.7% and 48.2 % of Nottingham grade I, II and III (p value=0.017) respectively. Among molecular group, high expression of Ki67 was observed 20.5% in Luminal A, 9.6% in Luminal B, 15.7% in Her2 enriched and 27.7% in triple negative groups (p= 0.017). There was no significant association observed in expression of Ki 67 among lymph node stage, tumour stage and Nottingham prognostic index. Conclusion: Higher Ki-67 reactivity is usually associated with higher-grade morphology of tumour. It can act as an independent predictor in assessment of tumour behavior. However, larger validation clinical studies are still required for confirmation of its importance and for routine practice.
个性化医学在乳腺癌的管理中发挥了非常重要的作用。增殖指数是其中的预后和预测因素之一,但遗憾的是,由于报告各不相同,尚未达成明确共识,也未将其常规应用于临床实践。本研究旨在观察 Ki-67 指数在巴基斯坦人群浸润性导管癌中的应用,采用圣加仑会议标准进行评估。
本前瞻性研究纳入了 83 例经组织学证实为原发性浸润性导管癌的患者。通过将肿瘤的 Ki-67 表达分为低(<15%)和高(>15%)两类来确定 Ki-67 的表达。采用统计学方法观察 Ki-67 与临床病理参数和分子分型(即 Luminal A、Luminal B、Her2 过表达和三阴性)之间的相关性。
83 例患者中,73.5%的患者 Ki-67 表达>15%(p 值<0.001)。Nottingham 分级为 I、II 和 III 的患者中,Ki-67 高表达(>15%)的比例分别为 3.6%、21.7%和 48.2%(p 值=0.017)。在分子分型中,Luminal A 型、Luminal B 型、Her2 过表达型和三阴性型的 Ki67 高表达比例分别为 20.5%、9.6%、15.7%和 27.7%(p=0.017)。Ki-67 表达与淋巴结分期、肿瘤分期和 Nottingham 预后指数之间无显著相关性。
较高的 Ki-67 活性通常与肿瘤形态学分级较高有关。它可以作为评估肿瘤行为的独立预测因子。然而,仍需要更大规模的验证性临床研究来确认其重要性,并将其常规应用于临床实践。